Galderma to Showcase the Latest Scientific and Innovative Breakthroughs in its Product Portfolio at the 2022 AAD Annual Meeting | Nation/World

FORT WORTH, Texas–(BUSINESS WIRE)–March 25, 2022–

Galderma, the leading company solely dedicated to advancing the future of dermatology, has announced that it will be attending the 2022 Annual Meeting of the American Academy of Dermatology to present its latest approved and investigational product updates. This includes presentations of clinical data in its product theaters, advisory boards and on-site booth activities as the AAD returns in person once again.

“We are excited to attend AAD to connect with the dermatology community and showcase our latest innovations and data across our entire dermatology portfolio,” said Baldo Scassellati Sforzolini, Global Head of Research and Development at Galderma . “Our presence underscores our commitment to developing and commercializing dermatological solutions to meet all skin needs.”

A considerable amount of new data will be presented at the AAD Congress in the form of abstracts and oral presentations for nemolizumab, a first-in-class investigational monoclonal antibody directed against the interleukin-31 (IL-31) receptor, in clinical development for the treatment of atopic dermatitis and prurigo nodularis.

Data on prurigo nodularis includes data on the efficacy of nemolizumab and its impact on itching and sleep disturbances. Seven other abstracts examine various aspects of the disease, including its prevalence, current treatment practices, and the effect of the disease on sleep, mental health disorders, and gastrointestinal and hepatobiliary diseases. Three atopic dermatitis abstracts examine the safety and efficacy of nemolizumab in adolescents and the impact of nemolizumab according to the EASI and Scorad components.

Galderma will present thirteen study abstracts regarding its investigational monoclonal antibody that targets the IL-31 receptor, nemolizumab. The data comes from phase 2 studies and real-world evidence. You can find more details about Galderma’s activities below.

Abstract number and title

First author

Presentation date/time (ET)

Abstract #35226: Characterization of Pain in Prurigo Nodularis: A Study Based on an Online Survey

Prachi Aggarwal, BA

Friday, March 25, 8:35 a.m. – 8:40 a.m.

Abstract #35303: Treatment Practices and Use of Web Resources for Prurigo Nodularis

Prachi Aggarwal, BA

Friday, March 25, 8:40 a.m. – 8:45 a.m.

Abstract #35351: Association between prurigo nodularis and gastrointestinal and hepatobiliary diseases in adults: a national cross-sectional study.

Adawi Walid

Friday, March 25, 8:55 a.m. – 9:00 a.m.

Abstract #35165: Efficacy, tolerance and cosmetic acceptability of an acne treatment specially designed for sensitive skin

James Q. Del Rosso, DO

Friday March 25

8:55 a.m. – 9:00 a.m.

Abstract no. 32846: DUAL study: trifarotene combined with doxycycline has proven its efficacy and safety in severe acne vulgaris

James Q. Del Rosso, DO

Friday March 25

9:00 a.m. – 9:05 a.m.

Abstract #33284: Efficacy of nemolizumab in atopic dermatitis: rapid impact on EASI and SCORAD components

Jean-David Bouaziz, MD, PhD

Friday, March 25 11:15 a.m. – 11:20 a.m.

Abstract #33317: Study of the pharmacokinetics, safety and efficacy of nemolizumab in adolescents with atopic dermatitis

Robert Sidbury, MD, MPH

Friday, March 25 11:20 a.m. – 11:25 a.m.

Abstract #34945: An in vitro evaluation of a niacinamide-panthenol-glycerin complex on skin barrier function, hydration and neuroinflammation

Dillon Nussbaum, BSc

Friday, March 25 11:55 a.m. – 12:00 p.m.

Abstract #34679: Association of the severity of atopic dermatitis in adults with a decrease in physical activity: a cross-sectional study

Gabrielle Schwartzman

Friday March 25

2:20 p.m. – 2:25 p.m.

Abstract #35218: Sleep disturbances in adults with prurigo nodularis are associated with increased circulating levels of C-reactive protein and adverse cardiovascular effects

Varsha Parthasarathy

Friday March 25, 2:25 p.m. – 2:30 p.m.

Abstract #33202: Prurigo nodularis and Mental Health Disorders in Hospitalized Patients in the United States

Thomas K Le

Saturday March 26, 1:25 p.m. – 1:30 p.m.

Abstract #34095: Observed and projected prevalence of prurigo nodularis in a commercially insured and Medicare-insured U.S. population

Shawn G. Kwatra

Saturday March 26, 2:40 p.m. – 2:45 p.m.

Abstract #33307: Nemolizumab is associated with rapid reduction of itching and sleep disturbances in patients with prurigo nodularis

Sonja Stander, MD

electronic poster

Additionally, Galderma will host four product presentations to discuss new research findings in our portfolio:



Date/Time (ET)


Acne: TWYNEO Cream & AKLIEF Cream

Revolutionary acne treatment: TWYNEO cream: the only dermatological combination of 0.1% tretinoin and 3% BPO for moderate to severe acne vulgaris

Friday March 25

10:30 a.m. – 11:15 a.m.

Theater 2

CETAPHIL Sensitive Skin

Advancing sensitive skin: diagnosis, morphological characteristics and epidemiology

Friday March 25

12:00 p.m. – 12:45 p.m.

Theater 1

Pediatric CETAPHIL

Pediatric atopic dermatitis: current developments

Saturday March 26

12:00 p.m. – 12:45 p.m.

Theater 2


A Neuroimmune Perspective on Itch and Skin Inflammation in Atopic Dermatitis and Prurigo Nodularis – Introducing IL-31

Sunday March 27

10:30 a.m. – 11:15 a.m.

Theater 2

A series of Speakers’ Forum talks will take place at Galderma booth #1117.



Date/Time (ET)


IL-31: A neuroimmune perspective on atopic dermatitis

Jonathan Silverberg, MD, PhD, MPH

Friday, March 25 12:10 p.m. – 12:25 p.m.

Galderma Booth #1117

Activate the power of the skin with PLLA

Susan H. Weinkle, MD

Friday, March 25 12:30 p.m. – 12:55 p.m.

Galderma Booth #1117

Galderma innovation

JP York, Ph.D., Galderma Medical Affairs

Saturday March 26 12:10 p.m. – 12:25 p.m.

Galderma Booth #1117

Revolutionary acne treatment: TWYNEO cream: the only dermatological combination of 0.1% tretinoin and 3% BPO for moderate to severe acne vulgaris

Omar Noor, MD, FAAD

Saturday March 26 12:30 p.m. – 12:55 p.m.

Galderma Booth #1117

The rheology of the Restylane collection of hyaluronic acid fillers

Deirdre Hooper, MD

Sunday March 27 12:10 – 12:55

Galderma Booth #1117

For more information on IL-31 and its role in the pathophysiology of atopic dermatitis and prurigo nodularis, visit

About atopic dermatitis

Atopic dermatitis (AD) is a chronic, debilitating inflammatory skin disease characterized by diffuse skin lesions and constant, severe itching. [1],[2] The reported prevalence of AD varies widely, ranging from 1% to 25% of the population depending on geography and age group. [3] AD can have a profound impact on the quality of life of patients, leading to sleep disturbances, psychological complications and causing secondary skin infections (both bacterial and viral). [4]

About nodular prurigo

Prurigo nodularis (PN) is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large areas of the body and associated intense and persistent itching. [5] Although PN can occur at any age, it is more likely to affect people between the ages of 40 and 69, frequently resulting in severe impairment of quality of life. [6]

The worldwide prevalence of PN is not well known as there are few studies describing the epidemiology of the disease. In the United States, the latest estimate is that PN affects 52.9 in every 100,000 people. [4] In the European context, rates between 0.65 and 11.1 per 10,000 inhabitants have been reported. In addition to natural variation, this relatively wide range of estimates is due in part to differences in case definition and representativeness of the populations studied. [6]

About nemolizumab

Nemolizumab is an investigational agent in clinical development for the treatment of atopic dermatitis and prurigo nodularis and its safety and efficacy have not been fully evaluated by any regulatory authority.

About Galderma

Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by total dedication to dermatology. We offer an innovative, science-based portfolio of brands and sophisticated services in aesthetics, consumer care and prescription medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior results. Because we understand that the skin we stand in shapes our life stories, we advance dermatology for every skin story. For more information:

The references

  1. Langan S et al. Atopic dermatitis. The Lancet. 2020;396(10247):345-360. DOI:
  2. Weidinger S et al. Atopic dermatitis. Natural journals. 2018. DOI: 10.1038/s41572-018-0001-z
  3. Silverberg, J, I. Public health burden and epidemiology of atopic dermatitis.283-289. 2017.
  4. Galderma. Data on file. To be presented at AAD 2022.
  5. Galderme. Data on file. Press release. Galderma presents new nemolizumab data to EADV. 2021.
  6. Morgan LI. Christopher. Epidemiology of prurigo nodularis in England. Accepted for publication in British Journal of Dermatology
  7. Saleem M et al. Interleukin-31 pathway and its role in atopic dermatitis: a systematic review. Treatment J Dermatolog. 2017;28(7):591-599. DOI: 10.1080/09546634.2017.1290205

See the source version on

CONTACT: Media Relations

Shannon Iwaniuk

Director, US Communications

[email protected]

+1 720 308 1336 Rachel Mooney

Director, Global Franchise Communications

[email protected]

+41 58 455 85 41 /+41 76 261 64 41



SOURCE: Galderma

Copyright BusinessWire 2022.

PUBLISHED: 03/25/2022 07:00 AM / DISK: 03/25/2022 07:02 AM

About Sally Dominguez

Check Also

How to get rid of blackheads

Although blackheads are a common form of acne and can affect anyone, studies show that …